Reported 24 days ago
Madrigal Pharmaceuticals' shares soared following Novo Nordisk's announcement of positive trial results for its weight-loss drug Wegovy, which is said to benefit patients with MASH, a fatty liver disease. Analysts believe this increased visibility for MASH could benefit Madrigal, whose own treatment may tackle aspects of the disease that Wegovy does not address.
Source: YAHOO